‎Could Semaglutide Drugs Like Ozempic and Wegovy Raise Suicide Risk? Experts Urge Caution Amid Conflicting Evidence

‎A newly published study in JAMA Network Open has raised urgent questions about the mental health risks associated with semaglutide-based medications, including widely prescribed drugs Ozempic and Wegovy. These glucagon-like peptide-1 receptor agonists (GLP-1 RAs), primarily used for managing type 2 diabetes and obesity, have surged in popularity—yet new safety concerns are prompting deeper scrutiny.

‎

‎New research links semaglutide drugs like Ozempic to increased suicidal thoughts, prompting expert caution and global health agency reviews.

‎Armend Nimani/AFP via Getty Images

‎

‎Researchers conducting the study utilized the World Health Organization’s global database of individual case safety reports to assess adverse psychological effects potentially linked to GLP-1 medications. Their analysis identified a disproportionately higher frequency of suicidal ideation reports among users of semaglutide compared to users of other drugs in the dataset.

‎

‎The data revealed a 45% increase in reports of suicidal thoughts linked to semaglutide, a statistically notable signal that the authors argue demands further investigation. Liraglutide, another GLP-1 RA, did not demonstrate a similar association, making the findings particularly specific to semaglutide.

‎

‎Concerns about a possible mental health impact first gained international traction in July 2023, when the European Medicines Agency launched a formal review after receiving multiple reports of suicidal thoughts tied to semaglutide and liraglutide. Subsequent reviews by the UK’s Medicines and Healthcare Products Regulatory Agency and the U.S. Food and Drug Administration followed. So far, no regulatory body has identified a definitive causal link.

‎

‎The authors of the JAMA study acknowledge their findings are based on a relatively small number of cases—only 0.35% of total adverse reports connected to semaglutide involved suicidal ideation. This low incidence rate underscores the complexity of attributing causality based on observational data alone.

‎

‎Further complicating the picture, a separate large-scale study published in Nature Medicine in January 2024 found no increased risk. In fact, that study, involving over 240,000 patients, concluded that individuals taking semaglutide for weight loss had lower rates of suicidal thoughts compared to those using other non-GLP-1 RA anti-obesity medications.

‎

‎Still, researchers behind the more recent JAMA analysis advise caution, especially for individuals with a personal or family history of psychiatric disorders. They recommend enhanced monitoring protocols and propose that packaging for all semaglutide-based drugs include updated mental health warnings—guidance partially reflected in the current FDA label for Wegovy.

‎

‎The divergence in findings highlights a broader challenge in pharmacovigilance: determining real-world psychiatric side effects from self-reported data. Though no conclusive evidence supports that semaglutide directly causes suicidal ideation, the reported association emphasizes the need for comprehensive, long-term studies.

‎

‎For patients currently using semaglutide medications, healthcare providers recommend continued use under medical supervision, especially in the absence of psychiatric history. Decisions about starting or continuing these drugs should involve individualized conversations between patients and their clinicians, weighing potential benefits against possible mental health risks.

‎

‎Mental health professionals and regulatory authorities continue to monitor the evolving data, with transparency and patient safety at the forefront of emerging treatment guidelines.